Biology of the Disease

The articles below are listed in chronological order, newest to oldest.

Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss (Zhu et al., 2023)

Small-cell carcinoma of the ovary hypercalcaemic type shows a wild-type immunohistochemical staining pattern of p53 (F. K. Kommoss et al., 2023)

The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms (Zhang et al., 2022)

The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer (Vaicekauskaitė et al., 2022)

Cellular context determines DNA methylation profiles in SWI/SNF ‐deficient cancers of the gynecologic tract (Kommoss et al., 2022)

SWI/SNF‐deficient undifferentiated malignancies: where to draw the line (Tessier-Cloutier et al., 2021)

SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy (Mardinian et al., 2021)

Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis (Auguste et al., 2020)

An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings (Lu & Shi, 2019)

The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity–independent genomic targeting (Pan et al., 2019)

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary (Xue et al., 2019)

Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type (Jelinic et al., 2016)

Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcemic type. (Karnezis et al., 2016)

The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type (Foulkes et al., 2016)

SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor) (Karanian-Philippe et al., 2015)

Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. (Ramos et al., 2014)

Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. (Jelinic et al., 2014)

Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. (Witkowski et al., 2014)

Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics (Gamwell et al., 2013)